ERα36 is involved in mammary tumor progression and resistance to drug treatment due to its ability to activate non-genomic signaling pathways such as the PI3K/AKT/mTORC1 and RAS/RAF/MEK/ERK pathways [275,276]. This evidence concerns the gene AKT1 and breast cancer.